Boston Scientific wins big book as Bayer brings hybrid

By Mike Turner
06 Nov 2019

Boston Scientific Corp, the US medical devices maker, obtained plenty of demand for its €900m bond as it made its debut in the Reverse Yankee market on Wednesday, while the euro corporate bond pipeline continues to fill for a flurry of issuance in November.

Bank of America, Barclays, and Goldman Sachs were bookrunners, and set initial price talk at 95bp over mid-swaps for the eight year issue rated Baa2/BBB-/BBB.

Demand swelled to more than €3bn and guidance was set at 75bp to 80bp. 

The bond was then priced at the tight end of guidance ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial